Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05119907 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Sacituzumab Govitecan in Patients With Solid Tumor

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Oct 2025 to Oct 2026v27
  2. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 300 to confirmed 53 · Study sites: 16 to 13 · Primary and study completion dates: Dec 2025 to Oct 2025 · 1 morev26 Show 4 more changesShow less
    • Enrollment target: estimated 300 to confirmed 53
    • Study sites: 16 to 13
    • Primary and study completion dates: Dec 2025 to Oct 2025
    • Study description shortened, about 11 words

    See this version in full on ClinicalTrials.gov ↗

  3. 2 versions Re-verified since Nov 11, 2024, no change to tracked fieldsv24-v25
  4. Site details revised at 4 of 16 sitesv23
  5. Site details revised at 6 of 16 sitesv22
Show 20 earlier versionsHide 20 earlier versions
  1. Re-verified, no change to tracked fieldsv21
  2. Study sites: 15 to 16v20
  3. 2 versions Re-verified since May 23, 2024, no change to tracked fieldsv18-v19
  4. Study sites: 13 to 15v17
  5. 10 versions Re-verified since Jun 27, 2023, no change to tracked fieldsv7-v16
  6. Study sites revised (13)v6 See this version in full on ClinicalTrials.gov ↗
  7. 2 versions Re-verified since Apr 12, 2023, no change to tracked fieldsv4-v5
  8. Study Status, Referencesv3
  9. Lead sponsor: Everest Medicines to Gilead Sciences Enrollment target: 180 to 300 · Primary completion date: Nov 2022 to Dec 2025 · Primary endpoint revised · 7 morev2 Show 10 more changesShow less
    • Enrollment target: 180 to 300
    • Primary completion date: Nov 2022 to Dec 2025
    • Primary endpoint revised
    • Study sites: 1 to 13
    • Start date: Sep 23, 2021 to Oct 12, 2021
    • Eligibility criteria shortened, about 62 words
    • Secondary endpoints: 3 to 10
    • Study description expanded, about 11 words
    • Study arms: 3 to 5
    • Study title expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Gilead Sciences
113 trials monitored
See 11 trials at risk
The goal of this study is to see how effective the study drug, sacituzumab govitecan-hziy, is in participants with solid tumor.
Trial Details
NCT Number NCT05119907
Lead Sponsor Gilead Sciences
Conditions Solid Tumor
Enrollment 53 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov